News summary

Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity

Source: PR Newswire • Published: 19 Nov 2026, 00:01

Summarized by Masters of Longevity from PR Newswire.

China's NMPA accepted an IND for LET003, an AI‑designed ACVR2A/2B antibody.

Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity
Key Takeaways
  • The IND covers LET003, an AI‑designed dual ACVR2A/2B antibody.
  • Preclinical data showed improved pharmacokinetics and enhanced fat reduction.
  • Animal studies found lean mass preservation but human efficacy remains unproven.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.